Retinal Vascular Resistance Significantly Correlates With Visual Acuity After 1 Year of Anti-VEGF Therapy in Central Retinal Vein Occlusion

Makiko Matsumoto¹, Kiyoshi Suzuma², Fumito Akiyama¹, Kanako Yamada¹, Shiori Harada¹, Eiko Tsuiki¹, and Takashi Kitaoka¹

¹ Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
² Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Kagawa University, Kagawa, Japan

Correspondence: Kiyoshi Suzuma, Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa Prefecture 761-0793, Japan. e-mail: suzuma@med.kagawa-u.ac.jp

Received: February 18, 2021
Accepted: August 30, 2021
Published: September 24, 2021

Keywords: central retinal vein occlusion; total capillary resistance; mean blur rate; vascular endothelial growth factor; laser speckle flowgraphy

Citation: Matsumoto M, Suzuma K, Akiyama F, Yamada K, Harada S, Tsuiki E, Kitaoka T. Retinal vascular resistance significantly correlates with visual acuity after 1 year of anti-VEGF therapy in central retinal vein occlusion. Transl Vis Sci Technol. 2021;10(11):19, https://doi.org/10.1167/tvst.10.11.19

Introduction

The degree of ischemia in patients with central retinal vein occlusion (CRVO) varies in accordance with both the individual and disease stage.¹ In addition, the loss of visual function due to CRVO depends strongly on the extent of macular edema and retinal ischemia development. The outcomes of visual acuity differ greatly depending on whether it is nonischemic type or ischemic type.¹,² As vascular endothelial growth factor (VEGF) is the primary mediator of macular edema and retinal angiogenesis,³–⁵ anti-VEGF agents, such as aflibercept, bevacizumab, and ranibizumab, have been used in treatments for CRVO-associated macular edema.

Although intravitreal injections of anti-VEGF agents can significantly reduce macular edema and improve visual acuity,⁶–¹⁰ this approach often results in no or only a temporary therapeutic benefit, even if patients receive multiple injections.¹¹–¹⁴
Previously, we evaluated mean blur rate (MBR), which reflects the retinal blood flow velocity, using a laser speckle flowgraphy (LSFG)-NAVI system (Softcare Co., Ltd., Fukuoka, Japan) in patients with CRVO. In addition, we reported that MBR after intravitreal bevacizumab (IVB) injection is strongly associated with the prognosis of visual acuity. In a recent study, we evaluated CRVO based on the aspect of the resistivity of all retinal vessels, termed total capillary resistance (TCR). CRVO was originally thought to be a disease caused by an increased resistance of the central retinal vein in lamina cribrosa. In CRVO, it is believed that as TCR increases MBR decreases accordingly. Therefore, based on this, we speculated that TCR would be useful for assessing the pathophysiology of CRVO. In the present study, we further used TCR to evaluate nonischemic CRVO cases and then reexamined the factors involved in the prognosis of visual acuity.

### Methods

We carried out this retrospective observational case series in accordance with the tenets of the Declaration of Helsinki and after receiving approval by the Institutional Review Board of Nagasaki University Hospital. We enrolled consecutive patients with macular edema related to CRVO in the study who had undergone anti-VEGF treatment at Nagasaki University Hospital between December 2010 and December 2018. Patients for whom we were unable to obtain proper measurements (e.g., those with cataracts with severe opacity, vitreous hemorrhage, poor mydriasis, or corneal opacity; those in which the nonperfusion area could not be accurately evaluated by fluorescein angiography), who had a history of vitreoretinal surgery, or who were classified as ischemic type were excluded. Next, we retrospectively observed patients as either the ischemic or nonischemic type. In our current study, we performed panretinal photocoagulation immediately after a case was identified as ischemic type. After the treatment, the patients were examined monthly and re-treated if the CRT was 300 μm or more. Subsequently, they were treated with a modified and extended regimen.

Sixty-seven nonischemic patients and 14 ischemic patients were evaluated at their first visit during the study period. Next, we retrospectively observed and divided the nonischemic cases into the following two groups based on the clinical course: nonischemic or converted. When evaluating these changes, fluorescein angiography was performed as needed (e.g., when visual acuity decreased, MBR decreased, bleeding increased), with the division made according to whether there were more than 10 disc areas of nonperfusion or narrower. At their first visit, nonischemic cases were classified according to whether they had converted to the ischemic type (converted group) or not (nonischemic group) on the final day of observation.

### LSFG Blood Flow Measurements

Measurements were obtained using the LSFG system. As has been previously described, use of the LSFG technique makes it possible to measure the optic disc blood flow. We evaluated microcirculation at the optic nerve head (ONH) by measuring the MBR of the ONH, and we evaluated total resistivity throughout all of the retinal vessels (ranging from the retinal artery, arterioles, capillaries, and venules to the central retinal vein) by measuring the TCR, as previously reported.

LSFG can analyze blood flow as a series of pulsatile blood flows over several cardiac cycles for 4 seconds. As a result, LSFG can detect peak-to-peak blood flow in the cardiac cycle. To evaluate peak-to-peak blood flow using LSFG, we calculated the beat strength (BS) as being proportional to the amplitude between the maximum and minimum blood flow. The formula for calculating BS can be viewed within the patent application WO/2018/003139, Blood Flow Dynamic Imaging Diagnosis Device and Diagnosis Method (https://patentscope2.wipo.int/search/en/detail.jsf?docId=WO2018003139). TCR, which is the new parameter for the resistivity of the retinal vein, is calculated based on the ONH for CRVO using the following equation:

$$\text{TCR} = (\text{BS in the area of ONH}) / \text{MBR}$$
tional value of the peak-to-peak blood flow corresponding to the major vessels in the ONH. As a result, the TCR represents the total resistivity throughout all of the retinal vessels (including the retinal artery, arterioles, capillaries, venules, and central retinal vein).

**Retinal Thickness Analysis**

CRT determinations were performed by OCT (Cirrus HD-OCT; Carl Zeiss Meditec, Jena, Germany) using the Macular Cube $512 \times 128$ scanning protocol, which measures the mean retinal thickness in the central 1000-μm-diameter area.

**Statistical Analysis**

In this study, the primary objective was to determine the presence of a correlation between retinal blood flow levels and the outcomes among patients receiving anti-VEGF treatment for macular edema secondary to CRVO. First, we compared outcomes between the nonischemic and converted groups using the Mann–Whitney $U$ test or Pearson’s $\chi^2$ test. The mean CRT and mean MBR before and after treatment in each group were compared using a paired $t$-test. In addition, we carried out linear regression analysis to evaluate measurement of the visual acuity at 1 year after the first anti-VEGF injection, as assessed using a logarithm of the minimum angle of resolution (logMAR) chart, and other factors, as well as tests of regression. Multiple regression analysis of the 63 cases with complete data was conducted. All statistical analyses were performed using R 3.5.2 (R Foundation for Statistical Computing, Vienna, Austria). The results are expressed as the mean ± standard deviation, unless otherwise indicated. Values of $P < 0.05$ were considered to indicate statistical significance.

**Results**

This study assessed a total of 67 eyes in 67 consecutive patients with nonischemic-type CRVO (36 males and 31 females; mean age, 68.4 ± 11.4 years). No patients had any prior treatment for macular edema related to CRVO. Among these 67 patients, 40, 12, and four had hypertension, diabetes mellitus, and cardiovascular disease, respectively, and 14 had no past clinical history. Of the 67 nonischemic eyes, nine (13.4%) converted to the ischemic type during the study. The mean duration from CRVO onset to the first anti-VEGF treatment was 1.1 ± 0.8 months.

Table 1 shows the characteristics of each group. No significant differences in gender, age, duration from CRVO onset to first anti-VEGF injection, VEGF concentration, number of anti-VEGF injections per year, or history were observed between the two groups.

Figure 1A shows the changes in the mean logMAR visual acuity for each group. Significant improvement was observed for the mean logMAR visual acuity of the nonischemic group (before treatment: 0.53 ± 0.36 vs. 1 year after the first injection: 0.21 ± 0.29; $P < 0.01$). In contrast, improvement in the visual acuity was not seen in the converted group (before treatment: 1.21 ± 0.54 vs. 1 year after the first injection: 1.00 ± 0.36; $P = 0.38$). A significant difference in mean logMAR visual acuity was found between the two groups before treatment and at 1 year after the first injection ($P < 0.01$).

Figure 1B shows the changes in the mean CRT in each group. In the nonischemic group, a significant decrease was observed in the mean CRT (before treatment: 593 ± 152 μm vs. 1 year after the first injection: 302 ± 98 μm; $P < 0.01$). Similarly, in the converted group, mean CRT at 1 year after the first injection was

| Table 1. Group Characteristics ($N = 67$)          | Nonischemic Group | Converted Group | $P$    | All     |
|--------------------------------------------------|-------------------|----------------|-------|--------|
| Number (male/female)                             | 58 (31/27)        | 9 (5/4)        | 0.83  | 67 (36/31) |
| Age (yr), mean ± SD                              | 68.4 ± 11.9       | 68.4 ± 7.9     | 0.98  | 68.4 ± 11.4 |
| Duration from CRVO onset to first visit (mo), mean ± SD | 1.0 ± 0.8        | 1.4 ± 1.1     | 0.26  | 1.1 ± 0.8   |
| VEGF concentration (pg/mL), mean ± SD            | 312 ± 347         | 705 ± 1183     | 0.38  | 376 ± 571   |
| Number of injections/yr, mean ± SD               | 4.2 ± 2.4         | 5.6 ± 1.9      | 0.07  | 4.3 ± 2.4   |
| History, n (%)                                   | 33 (56.9)         | 7 (77.8)       | 0.23  | 40 (59.7)   |
| Hypertension                                     | 11 (19.0)         | 1 (11.1)       | 0.49  | 12 (17.9)   |
| Diabetic mellitus                                | 4 (6.9)           | 0 (0)          | 0.55  | 4 (6.0)     |
Significant improvement in mean logMAR visual acuity was observed in the nonischemic group (before treatment: 0.53 ± 0.36 vs. 1 year after the first anti-VEGF injection: 0.21 ± 0.29; \( P < 0.01 \)). In contrast, improvement in visual acuity was not seen in the converted group (before treatment: 1.21 ± 0.54 vs. 1 year after the first anti-VEGF injection: 1.00 ± 0.36; \( P = 0.38 \)). A significant difference in mean logMAR visual acuity before treatment and at 1 year after the first anti-VEGF injection was found between the two groups \( (P < 0.01, \text{Mann–Whitney } U \text{ test}) \).

Figure 1C shows the change in the mean MBR in each group. In the nonischemic group, mean MBR significantly increased (before treatment: 21.0 ± 6.8 vs. 1 year after the first injection: 30.3 ± 11.4; \( P < 0.01 \)). In the converted group, however, the MBR was unchanged (before treatment: 18.0 ± 9.8 vs. 1 year after the first injection: 11.9 ± 6.2; \( P = 0.15 \)). The differences between the mean MBR values at 1 year after the first injection in the nonischemic versus the converted group were statistically significant \( (P < 0.01) \).

Figure 1D shows the changes in the mean TCR in each group, with a significant decrease noted for TCR in the nonischemic group after the anti-VEGF treatment (before treatment: 1.31 ± 0.63 vs. 1 year after the first anti-VEGF injection: 1.00 ± 0.42; \( P < 0.01 \)). In the converted group, however, TCR was unchanged after the anti-VEGF treatment (before treatment: 1.11 ± 0.36 vs. 1 year after the first anti-VEGF injection: 1.43 ± 0.67; \( P = 0.17 \)).

(E–H) Time course of changes for mean logMAR visual acuity (E), CRT (F), MBR (G), and TCR (H) in each group.
Figure 2. Distribution map showing logMAR visual acuity and MBR (A) before treatment and (B) at 1 year after the first treatment. A negative correlation was observed between logMAR visual acuity and MBR (A) before treatment \( (R = -0.30; P = 0.01) \) and (B) at 1 year after the first anti-VEGF injection \( (R = -0.66; P < 0.01) \).

0.23 vs. 1 year after the first injection: \( 1.43 \pm 0.67; P = 0.17 \).

Figures 1E to 1H show the time course of changes for the mean logMAR visual acuity, CRT, MBR, and TCR in each group, respectively. The mean CRT tended to decrease after treatment in both groups (Fig. 1F). In addition, the mean TCR tended to decrease in both groups at 1 month after the first injection, with the mean visual acuity also tending to improve at 1 month after the treatment. Subsequently, the mean TCR tended to increase and the mean visual acuity tended to decrease in the converted group. In contrast, in the nonischemic group, the mean TCR remained low and the mean visual acuity remained high (Figs. 1E, 1H). With regard to MBR, the nonischemic group tended to increase, and the converted group tended to decrease (Fig. 1G).

A negative correlation was found between logMAR visual acuity and MBR before treatment \( (R = -0.30; P = 0.01) \) (Fig. 2A) and at 1 year after the first injection \( (R = -0.66; P < 0.01) \) (Fig. 2B). Although no correlation was found between logMAR visual acuity and TCR before treatment \( (R = 0.01; P = 0.93) \), but (B) a significant positive correlation was found at 1 year after the first anti-VEGF injection \( (R = 0.46; P < 0.01) \).

Our investigation revealed significant correlations between logMAR visual acuity at 1 year after the first injection and other factors (Table 2), as well as with age \( (R = 0.29; P = 0.02, \text{linear regression analysis}) \), number of anti-VEGF injections per year \( (R = 0.29; P = 0.02) \), presence or absence of hypertension \( (R = 0.27; P = 0.03) \), CRT before treatment \( (R = 0.32; P < 0.01) \), MBR at 1 month after the first injection...
Discussion

Anti-VEGF treatment has been shown to be highly effective for macular edema secondary to CRVO, but not in all cases.\textsuperscript{11–14,22} There were several cases of macular edema recurrence in the present study. A previous study reported that 15% and 34% of cases converted from the nonischemic to the ischemic type at 4 months and 3 years, respectively.\textsuperscript{1} The percentage of converted cases in this study, with a follow-up period of 12 months, was 13.4%, which could be related to the actual anti-VEGF treatment. According to the Rubeosis Anti-VEGF (RAVE) trial, VEGF blockade delayed but did not ameliorate the risk of neovascular complications.\textsuperscript{23} Thus, the reason why only a small number of cases converted from the nonischemic to the ischemic type in the present study might have been because the anti-VEGF therapy delayed the time to conversion to ischemia. Advanced age is a well-known risk factor for CRVO,\textsuperscript{24,25} as is age among patients who have received bevacizumab therapy.\textsuperscript{11} In the present study, a strong and significant correlation was found between age and logMAR visual acuity at 1 year after the first anti-VEGF injection ($R = 0.29; P = 0.02$). The results of the BRAVO and CRUISE trials indicated that initial treatment should be started immediately in patients with CRVO.\textsuperscript{26} In the present study, no difference in the duration from CRVO onset to the first visit was found between the two groups. In our previous study (mean follow-up period, 19.7 ± 8.4 months; treated with IVB), the number of times was significantly different between the two groups (nonischemic group: 4.3 ± 3.2 times vs. converted group: 13.0 ± 7.2 times; $P = 0.02$, Mann–Whitney U test).\textsuperscript{16} However, there was no significant difference observed for the number of anti-VEGF injections seen during the 12-month period in the present study (converted group: 5.6 ± 1.9 times vs. nonischemic group: 4.3 ± 2.4 times; $P = 0.07$). Furthermore, a strong and significant correlation was found between logMAR visual acuity at 1 year after the first injection and the number of anti-VEGF injections per year ($R = 0.29; P = 0.02$). These findings suggest that frequent anti-VEGF treatments do not necessarily improve the grade of ischemia. Anti-VEGF therapy has also been reported to attenuate increases in areas of nonperfusion.\textsuperscript{8,27–29} In contrast, the RAVE trial reported that VEGF blockade delayed but did not ameliorate the risk of neovascular complications.\textsuperscript{23} Therefore, this effect might be limited based on the grade of ischemia. Hypertension has long been known to be a risk factor for CRVO.\textsuperscript{30,31} In the present study, 40 of 67 patients (59.7%) had a history of hypertension, which was not as high as previously reported (89.2\%).
Table 2. Correlations With logMAR Visual Acuity After 1 Year

|                        | Correlation Coefficient | P     |
|------------------------|-------------------------|-------|
| Gender                 | 0.008                   | 0.95  |
| Age                    | 0.29                    | 0.02a |
| Duration from CRVO onset to first visit (mo) | 0.18 | 0.13 |
| VEGF (pg/mL)           | 0.12                    | 0.43  |
| Number of anti-VEGF injections/yr | 0.29 | 0.02a |
| History                |                         |       |
| Hypertension           | 0.27                    | 0.03a |
| Diabetic mellitus      | -0.07                   | 0.56  |
| Cardiovascular disease | 0.08                    | 0.51  |
| CRT before treatment   | 0.32                    | <0.01b|
| CRT 1 mo after first anti-VEGF injection | 0.01 | 0.93 |
| CRT 1 yr after first anti-VEGF injection | 0.19 | 0.13 |
| OPP before treatment   | 0.17                    | 0.18  |
| OPP 1 mo after first anti-VEGF injection | 0.05 | 0.67 |
| OPP 1 yr after first anti-VEGF injection | 0.03 | 0.98 |
| MBR before treatment   | -0.15                   | 0.21  |
| MBR 1 mo after first anti-VEGF injection | -0.44 | <0.01b |
| MBR 1 yr after first anti-VEGF injection | -0.66 | <0.01b |
| TCR before treatment   | 0.04                    | 0.73  |
| TCR 1 mo after first anti-VEGF injection | 0.13 | 0.32 |
| TCR 1 yr after first anti-VEGF injection | 0.46 | <0.01b |

OPP, ocular perfusion pressure.

aP < 0.05.
bP < 0.01.

Table 3. Results of the Multiple Linear Regression Analysis (Dependent Factor: logMAR Visual Acuity at 1 Year After the First Anti-VEGF Injection)

|                        | Estimate | Standard Error | T     | P   |
|------------------------|----------|----------------|-------|-----|
| Hypertension           | 0.15     | 0.087          | 1.70  | 0.09|
| CRT before treatment   | 0.26     | 0.088          | 2.98  | <0.01|
| MBR 1 yr after first anti-VEGF injection | -0.51 | 0.091 | -5.61 | <0.01|
| TCR 1 yr after first anti-VEGF injection | 0.32 | 0.094 | 3.45 | <0.01|

and 89.7%). However, patients with hypertension had a poor prognosis for the visual acuity ($R = 0.27; P = 0.03$).

In line with previous studies, mean CRT significantly decreased at 1 year after the first treatment in both groups. Before treatment, although the CRT was significantly higher in the converted group, no difference was observed at 1 year after the first treatment. Post-treatment CRT was not correlated with logMAR visual acuity after 1 year, although CRT before treatment was correlated with logMAR visual acuity after 1 year ($R = 0.32; P < 0.01$). Although improvement in mean visual acuity was seen at 1 year after the first treatment in the nonischemic group, no significant improvement was observed in the converted group. Between the two groups, mean logMAR visual acuity was significantly poor in the converted group before and at 1 year after the first treatment. Therefore, as previously reported, poor visual acuity before treatment may result in subsequent poor visual acuity after treatment.

We previously reported that patients with a good response to IVB showed reduced CRT and increased MBR after treatment. Although a comparison of the two groups revealed no significant difference in mean MBR before treatment (nonischemic group: 21.0 ± 6.8 vs. converted group: 18.0 ± 9.8), we did find a significant difference in mean MBR at 1 year after the first treatment.
injection (nonischemic group: 30.3 ± 11.4 vs. converted group: 11.9 ± 6.2; \( P < 0.01 \)). In addition, a significant increase in MBR was seen in the nonischemic group after treatment. In contrast, MBR in the converted group remained unchanged after treatment. Regarding TCR, a significant decrease was seen in only the nonischemic group at 1 year after the first treatment (before treatment: 1.31 ± 0.63 vs. 1 year after treatment: 1.00 ± 0.42; \( P < 0.01 \)). Based on the time course of changes observed for each index from Figures 1E to 1H, the following is suggested. The prognosis may be good in cases where the TCR decreases and the MBR increases after anti-VEGF treatment. Cases in which the TCR has decreased after anti-VEGF treatment but for which the MBR cannot be raised may result in ischemia. Thus, this suggests that it would be very useful to evaluate MBR and TCR after anti-VEGF treatment in patients with macular edema associated with CRVO. We speculate that, in the converted group, the high TCR value observed between 3 months and 1 year may be due to vascular occlusion and increases in the vascular resistance.

A significant negative correlation was found between logMAR visual acuity and MBR both before treatment (\( R = -0.30; P = 0.01 \)) and at 1 year after treatment (\( R = -0.66; P < 0.01 \)), with the correlation becoming stronger after treatment. Although no correlation was observed between TCR and logMAR visual acuity before treatment, a significant correlation was found at 1 year after treatment (\( R = 0.46; P < 0.01 \)). Similarly, no correlation was found between MBR and TCR before treatment, whereas a significant negative correlation was found at 1 year after treatment (\( R = -0.37; P < 0.01 \)).

Multiple linear regression analysis confirmed that MBR had the strongest independent correlation with visual acuity after treatment, followed by TCR. These findings suggest that outcomes in patients with CRVO can be assessed by blood flow after anti-VEGF treatment. Therefore, patients who have increased MBR and decreased TCR after anti-VEGF treatment might require only anti-VEGF therapy. However, additional treatment may be needed for patients with decreased MBR and increased TCR.

Early peripheral laser photoocoagulation of a nonperfused retina has been shown to improve vision in patients with CRVO, and laser photoocoagulation has been reported to increase retinal blood flow in eyes with CRVO. Therefore, we speculate that early photoocoagulation might lead to better outcomes.

This retrospective study had several limitations. First, the number of patients, particularly in the converted group, was low, which could make a definitive statistical interpretation of our results difficult. Second, as this was a retrospective study, fluorescein angiography was not always repeated in all cases. As a result, it cannot be ruled out that some of the cases that were classified as being in the nonischemic group may have had an increased nonperfusion area. Third, we only undertook one approach for the blood flow measurements. Noninvasive laser Doppler instrumentation, such as LSFG, can be used to measure the absolute value of retinal blood flow. Therefore, different measurement methods (for example, the use of laser Doppler instrumentation) should ideally be employed when undertaking these types of studies.

In conclusion, evaluating blood flow measurements (MBR and TCR) after an anti-VEGF injection are useful in helping to determine the outcomes of the subsequent treatment strategies in patients with CRVO. Furthermore, MBR and TCR are independent factors. This study will be useful in developing clinically relevant technologies.

**Acknowledgments**

The authors thank Misaki Morita, Eriko Fujimoto and Miwa Takahashi, the orthoptists who performed inspections in this study.

Supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture (25861638) and by the Japan National Society.

Disclosure: M. Matsumoto, None; K. Suzuma, None; F. Akiyama, None; K. Yamada, None; S. Harada, None; E. Tsuiki, None; T. Kitaoka, None

**References**

1. Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. *Arch Ophthalmol.* 1997;115:486–491.
2. Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. *Ophthalmology.* 2011;118:119–133.e1–e2.
3. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N Engl J Med.* 1994;331:1480–1487.
4. Aiello LP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. *Ophthalmic Res.* 1997;29:354–362.
5. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. *Arch Ophthalmol*. 2002;120:1644–1650.
6. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. *Ophthalmic Surg Lasers Imaging*. 2005;36:336–339.
7. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. *Retina*. 2006;26:279–284.
8. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. *Ophthalmology*. 2011;118:2041–2049.
9. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. *Am J Ophthalmol*. 2013;155:429–437.e7.
10. Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. *Ophthalmology*. 2014;121:202–208.
11. Ach T, Hoeh AE, Schaal KB, Scheuerle AF, Dithmar S. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. *Graefes Arch Clin Exp Ophthalmol*. 2010;248:155–159.
12. Papakostas TD, Lim L, van Zyl T, et al. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab. *Eye (Lond)*. 2016;30:79–84.
13. Kida T, Tsujikawa A, Muraoka Y, et al. Cotton wool spots after anti-vascular endothelial growth factor therapy for macular edema associated with central retinal vein occlusion. *Ophthalmologica*. 2016;235:106–113.
14. Konidaris V, Al-Hubeshy Z, Tsaousis KT, Gorgoli K, Banerjee S, Empesilidis T. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab. *Int Ophthalmol*. 2018;38:207–213.
15. Matsumoto M, Suzuma K, Fukazawa Y, et al. Retinal blood flow levels measured by laser speckle flowgraphy in patients who received intravitreal bevacizumab injection for macular edema secondary to central retinal vein occlusion. *Retin Cases Brief Rep*. 2014;8:60–66.
16. Matsumoto M, Suzuma K, Yamada Y, Tsuiki E, Fujikawa A, Kitaoka T. Retinal blood flow after intravitreal bevacizumab is a predictive factor for outcomes of macular edema associated with central retinal vein occlusion. *Retina*. 2018;38:283–291.
17. Matsumoto M, Suzuma K, Akiyama F, et al. Retinal microvascular resistance estimated from waveform analysis is significantly higher with a threshold value in central retinal vein occlusion. *Transl Vis Sci Technol*. 2020;9:4.
18. Central Vein Occlusion Study Group. Baseline and early natural history report. *Arch Ophthalmol*. 1993;111:1087–1095.
19. Sugiyama T, Araie M, Riva CE, Schmetterer L, Orgul S. Use of laser speckle flowgraphy in ocular blood flow research. *Acta Ophthalmol*. 2010;88:723–729.
20. Tamaki Y, Araie M, Kawamoto E, Eguchi S, Fujii H. Non-contact, two-dimensional measurement of tissue circulation in choroid and optic nerve head using laser speckle phenomenon. *Exp Eye Res*. 1995;60:373–383.
21. Kikuchi S, Miyake K, Tada Y, et al. Laser speckle flowgraphy can also be used to show dynamic changes in the blood flow of the skin of the foot after surgical revascularization. *Vascular*. 2019;27:242–251.
22. Campochiaro PA, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. *Ophthalmology*. 2014;121:209–219.
23. Brown DM, Wykoff CC, Wong TP, Mariani AF, Croft DE, Schuetzle KL. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial. *Retina*. 2014;34:1728–1735.
24. Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. *Am J Ophthalmol*. 1994;117:429–441.
25. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. *Arch Ophthalmol*. 2008;126:513–518.
26. Thach AB, Yau L, Hoang C, Tuomi L. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. *Ophthalmology*. 2014;121:1059–1066.
27. Terui T, Kondo M, Sugita T, et al. Changes in areas of capillary nonperfusion after intravitreal...
injection of bevacizumab in eyes with branch retinal vein occlusion. *Retina.* 2011;31:1068–1074.

28. Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. *Ophthalmology.* 2013;120:795–802.

29. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. *Ophthalmology.* 2011;118:1594–1602.

30. Cugati S, Wang JJ, Knudtson MD, et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. *Ophthalmology.* 2007;114:520–524.

31. Yasuda M, Kiyohara Y, Arakawa S, et al. Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the Hisayama study. *Invest Ophthalmol Vis Sci.* 2010;51:3205–3209.

32. Rehak M, Tilgner E, Franke A, Rauscher FG, Brosteanu O, Wiedemann P. Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (results of a proof of concept study). *Graefes Arch Clin Exp Ophthalmol.* 2014;252:745–752.

33. Arvas S, Ocakoglu O, Ozkan S. The capillary blood flow in ischaemic type central retinal vein occlusion: the effect of laser photoacoagulation. *Acta Ophthalmol Scand.* 2002;80:490–494.

34. Yoshida A, Feke GT, Green GJ, et al. Retinal circulatory changes after scleral buckling procedures. *Am J Ophthalmol.* 1983;95:182–188.

35. Nagaoka T, Sato E, Takahashi A, Yokota H, Sogawa K, Yoshida A. Impaired retinal circulation in patients with type 2 diabetes mellitus: retinal laser Doppler velocimetry study. *Invest Ophthalmol Vis Sci.* 2010;51:6729–6734.

36. Riva CE, Cranstoun SD, Grunwald JE, Petrig BL. Choroidal blood flow in the foveal region of the human ocular fundus. *Invest Ophthalmol Vis Sci.* 1994;35:4273–4281.

37. Nagaoka T, Kitaya N, Sugawara R, et al. Alteration of choroidal circulation in the foveal region in patients with type 2 diabetes. *Br J Ophthalmol.* 2004;88:1060–1063.